Manuel Villareal, MD
Allergy & Immunology · Lakeside Park, KYNPI 1255389409
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.9% of the total across 276 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,729 and has fallen 91.7% since, to $143 in 2025. That places this record below the midpoint for allergy & immunology clinicians in KY, where the typical reported total is $7,092.
Across 276 payments — averaging $26.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Sanofi$895
- Shionogi Inc$822
- Regeneron Healthcare Solutions, Inc.$535
- AstraZeneca$475
- Optinose US, Inc.$370
- plus $3K from 24 others
Across 130 payments — averaging $4043.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$159K
- Merck$111K
- Hikma Pharmaceuticals USA$64K
- Novartis$53K
- Astrazeneca AB$41K
- Shionogi Inc$38K
- plus $60K from 3 others
What the payments were for
- Travel & lodging$5948%
- Food & beverage$6,76691%
- Education$801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 61 | $1,259 |
| Sanofi | 25 | $895 |
| Shionogi Inc | 7 | $822 |
| Regeneron Healthcare Solutions, Inc. | 13 | $535 |
| AstraZeneca | 21 | $475 |
| Optinose US, Inc. | 18 | $370 |
| Pfizer | 18 | $345 |
| CSL Behring | 18 | $328 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $289 |
| Teva Pharmaceuticals USA, Inc. | 17 | $284 |
| Covis Pharma GmbH | 12 | $222 |
| Grifols USA, LLC | 12 | $204 |
| Merck | 1 | $157 |
| Octapharma USA, Inc. | 3 | $150 |
| Alk-abello, Inc | 7 | $142 |
| Urovant Sciences Inc | 1 | $125 |
| Stryker | 1 | $125 |
| Kaleo, Inc. | 7 | $106 |
| Novartis | 4 | $98 |
| AbbVie | 1 | $85 |
| Amgen | 4 | $84 |
| Sanofi-aventis U.S. LLC | 1 | $68 |
| Blueprint Medicines Corporation | 2 | $56 |
| Biocryst US Sales Co., LLC | 2 | $51 |
| Shire North American Group Inc | 3 | $50 |
| Genentech USA, Inc. | 2 | $47 |
| Mylan Specialty L.p. | 1 | $22 |
| Hospira, Inc. | 1 | $16 |
| Pharming Healthcare, Inc. | 1 | $16 |
| Hologic Sales And Service, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,440 in reported general payments places this provider in the 50th percentile of 66 allergy & immunology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 15 | $66,969 |
| Dupixent PenDupilumab | 11 | $40,999 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $27,322 |
| Advair HfaFluticasone Propion/Salmeterol | 52 | $23,113 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $14,096 |
| Arnuity ElliptaFluticasone Furoate | 46 | $13,633 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $13,192 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 64 | $9,284 |
| Epinephrine | 39 | $8,756 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $7,695 |
| Azelastine Hcl | 179 | $4,455 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 27 | $3,196 |
| Fluticasone Propionate | 132 | $2,373 |
| Mometasone Furoate | 46 | $1,990 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 63 | $1,802 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,259 | $55,05199 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $475 | $20,88638 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 66 allergy & immunology providers in Kentucky.
Other allergy & immunology in Lakeside Park
- Lee CloreOwensboro$841K
- James SublettLouisville$588K
- Hans OttoFlorence$381K
- Stephen PollardLouisville$301K
- Douglas LotzLouisville$199K
- James SublettLouisville$194K
- Timothy FranxmanLouisville$162K
- Jeremy JonesLouisville$149K
- Rajiv AroraLexington$144K
- Mark CorbettLouisville$138K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.